Working… Menu

Sjogrens Syndrome Measured by Ultrasound

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03411850
Recruitment Status : Active, not recruiting
First Posted : January 26, 2018
Last Update Posted : May 11, 2021
Bristol-Myers Squibb
Information provided by (Responsible Party):
Arthritis & Rheumatism Associates, P.C.

Brief Summary:
Ultrasound study focused on salivary gland outcomes in Sjogren's subjects

Condition or disease Intervention/treatment Phase
Sjogren's Syndrome Biological: Orencia Other: Placebo Phase 2

Detailed Description:
A 32 week ultrasound study for subject diagnosed with Sjogren's Syndrome. Subjects will receive Orencia (Abatacept) as intervention therapy during this trial.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single (Participant)
Primary Purpose: Other
Official Title: Disease Modification in Sjogrens Syndrome Measured by Ultrasound: A Pilot Study
Study Start Date : May 2016
Estimated Primary Completion Date : May 2021
Estimated Study Completion Date : December 2021

Resource links provided by the National Library of Medicine

Drug Information available for: Abatacept

Arm Intervention/treatment
Active Comparator: Orencia (Abatacept)
Orencia (Abatacept) Intravenous (IV) or Subcutaneous (SQ) injection
Biological: Orencia
FDA approved biologic
Other Name: Abatacept

Placebo Comparator: Placebo
Placebo (saline solution) given Intravenous (IV) or Subcutaneous (SQ)
Other: Placebo
Other Name: Saline

Primary Outcome Measures :
  1. Salivary gland changes [ Time Frame: 32 weeks ]
    Salivary gland changes detected by ultrasound imaging with elastography

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Subjects diagnosed with Sjogren's Syndrome

Exclusion Criteria:

  • Subjects previously diagnosed with Sarcoidsis
  • Subjects with positive for Hepatitis B, Hepatitis C, HIV
  • Subjects diagnosed with Cancer within 5 years of screening

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03411850

Layout table for location information
United States, Maryland
The Center for Rheumatology and Bone Research a division of Arthritis and Rheumatism Associates, P.C.
Wheaton, Maryland, United States, 20902
Sponsors and Collaborators
Arthritis & Rheumatism Associates, P.C.
Bristol-Myers Squibb
Layout table for additonal information
Responsible Party: Arthritis & Rheumatism Associates, P.C. Identifier: NCT03411850    
Other Study ID Numbers: BMS IM101-560
First Posted: January 26, 2018    Key Record Dates
Last Update Posted: May 11, 2021
Last Verified: May 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Sjogren's Syndrome
Pathologic Processes
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Salivary Gland Diseases
Mouth Diseases
Stomatognathic Diseases
Dry Eye Syndromes
Lacrimal Apparatus Diseases
Eye Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Immune Checkpoint Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents